Monday July 16, 2018
Home India Justin Trudea...

Justin Trudeau’s Government Selects Indo-Canadian Rana Sarkar as Consul-General to San Francisco

The Indo Canadian is also a member of the team that is negotiating NAFTA

0
//
102
Indo-Canadian
Rana Sarkar. Wikimedia
Republish
Reprint

August 05, 2017: Rana Sarkar, an Indo-Canadian who was until recently national director for high growth markets at the Toronto-based multi-national KPMG, has been named by Prime Minister Justin Trudeau’s Liberal government as Canadas Consul-General to San Francisco.

Simultaneously, Sarkar has also been named a member of the high-profile Canadian official team for renegotiating the North American Free Trade Agreement (NAFTA) with the US and Mexico.

The Indo-Canadian community is elated over this very high profile appointment:

“Rana Sarkar (previously President of Canada-India Business Council) brings an impressive array of skills to his new position as Consul General in San Francisco,” says Kasi Rao, currently President of Canada-India Business Council and Vice-President of Asia-Pacific Foundation. “First, Rana is a global Canadian and has operated in multiple geographies – Canada, UK, and India. Second, he has brought individual networks and made them into institutional ones.

ALSO READ: Multiple Gender Identity Debate: Canada Passes Bill C-16

“Rana has maintained an abiding interest in the ideas and innovation space and therefore will be adept at positioning the Canadian advantage in a critically important global city of San Francisco.”

Gary Comerford, who till recently was President of C-IBC, says in an interview that Sarkar “will be a very strong addition to the Canadian-US trade team. His knowledge and considerable expertise in the areas of international trade will be invaluable as the NAFTA agreement is modernized.”

Sarkar was also a Liberal Party candidate for the federal riding of Don Valley North (in Toronto) in 2014 but was not successful and he later became a member of Prime Minister Justin Trudeau’s team of advisers.

Sarkar was earlier visiting lecturer at the London School of Economics and Political Science and more recently Senior Fellow at the Munk School of Global Affairs, University of Toronto.

Appointment of Sarkar in this high profile position is amongst a series of appointments of Indo-Canadians made by the Justin Trudeau government. They include four Indo-Canadian federal ministers: Amarjeet Sohi (Minister for Infrastructure and Communities); Bardish Chagger (Minister for Small Business and Tourism and House Leader); Harjit Singh Sajjan (Minister for National Defense); and Navdeep Bains (Minister for Innovation, Science and Economic Development).

More recently Trudeau named Anil Arora as Canada’s Chief Statistician. Two other high profile appointments include Sabi Marwah and Ratna Omidvar as Senators. There are 19 Indo-Canadian Members of the House of Commons, 18 of whom are Liberals. (IANS)

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)